Related Experiment Video
Updated: Mar 3, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Coenzyme Q10 Supplementation in a Child with Biallelic COQ8A Variants: A Case Report
Hirotaka Motoi1, Risa Watanabe1, Ayano Shirai1
1Department of Children's Medical Center, Yokohama City University Medical Center, Yokohama, Japan.
Insights
Coenzyme Q10 (CoQ10) supplementation improved cerebellar ataxia and intellectual disability in a child with COQ8A deficiency. This highlights the potential benefits of early diagnosis and CoQ10 therapy for pediatric neurological disorders.
Area of Science:
- Genetics
- Neurology
- Biochemistry
Background:
- Pathogenic variants in COQ8A cause primary coenzyme Q10 (CoQ10) deficiency, leading to childhood-onset cerebellar ataxia and developmental delay.
- Pediatric cases of COQ8A deficiency are rarely reported, and evidence for CoQ10 supplementation in children is limited.
Introduction:
Pathogenic variants in COQ8A cause a rare form of primary coenzyme Q10 (CoQ10) deficiency that can lead to childhood-onset cerebellar ataxia and developmental delay. However, reports of pediatric cases remain limited, and evidence regarding therapeutic response to CoQ10 supplementation in children is still scarce.
Case Presentation:
We report a 7-year-old boy with compound heterozygous COQ8A variants who presented with progressive cerebellar ataxia and intellectual disability. Oral CoQ10 supplementation was initiated at a dose of 10 mg/kg/day after institutional ethics approval. During 1 year of treatment, the Scale for the Assessment and Rating of Ataxia (SARA) score improved from 17 to 9, and serum CoQ10 concentration increased from 622 to 9.100 ng/mL. Mild cognitive improvement was also observed, with the intelligence quotient increasing from 53 to 64. Brain MRI demonstrated radiological stabilization of cerebellar atrophy. No adverse effects related to CoQ10 supplementation were observed throughout the treatment period.
Conclusion:
This case demonstrates the clinical benefit and safety of CoQ10 supplementation in pediatric-onset COQ8A-related ataxia. Early genetic diagnosis and timely initiation of CoQ10 therapy may lead to meaningful neurological improvement and stabilization of disease progression in affected children.
Related Concept Videos
Animal Mitochondrial Genetics
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Cofactors and Coenzymes
Cofactors and Coenzymes
Cofactors can be metallic ions or organic molecules called coenzymes. These types of helper...
Cystic Fibrosis: Management
Sinus disease and chronic...

